PASRITAMIG
UNII NDM64RSJ42

Substance Identification & Data

This profile provides standardized clinical and technical data for Pasritamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) NDM64RSJ42.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2921676-04-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

NDM64RSJ42

CAS Registry Number

2921676-04-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PASRITAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C180825

National Cancer Institute reference terminology for clinical and research data.

INN ID

13153

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-157

Identifier assigned by the United States Adopted Names Council.

Substance Type

Pasritamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Pasritamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Pasritamig

Common Names & Synonyms

H-gamma1 heavy chain Homo sapiens, anti-KLK2 (1-455) [VH (Homo sapiens IGHV4-59*01 (100%) -(IGHD) -IGHJ6*01 (94.4%), CDR-IMGT [8.7.19] (26-33.51-57.96-114)) (1-125) -Homo sapiens IGHG1*03v G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, G1v14-67 CH2 A1.3, A1.2, S27, G1v68 CH3 V6, L22, L79, W81 (CH1 R120>K (222) (126-223), hinge 1-15 (224-238), CH2 L1.3>A (242), L1.2>A (243), D27>S (273) (239-348), CH3 T6>V (358), E12 (364), M14 (366), T22>L (374), K79>L (400), T81>W (402) (349-453), CHS (454-455)) (126-455)], (228-214')-disulfide with L-kappa light chain Homo sapiens, anti-KLK2 (1'-214') [V-KAPPA (Homo sapiens IGKV1-9*01 (97.9%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; scFvkh-G1(h-CH2-CH3) heavy chain humanized, anti-CD3E (1''-475'') [V-KAPPA (Homo sapiens IGKV1-39*01 (86.3%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27''-32''.50''-52''.89''-97'')) (1''-107'') -20-mer (GGSEGKSSGSGSESKSTGGS) linker (108''-127'') -VH (Homo sapiens IGHV3-21*01 (89.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.9] (153''-160''.178''-185''.224''-232'')) (128''-243'') -Homo sapiens IGHG1*03 h-CH2-CH3, nG1m1 CH3 E12, M14, G1v14-67 CH2 A1.3, A1.2, S27, G1v37 h S5, G1v69 CH3 V6, Y7, A85.1, V86 (hinge 1-15 C5>S (248'') (244''-258''), CH2 L1.3>A (262''), L1.2>A (263''), D27>S (293'') (259''-368''), CH3 T6>V (378''), L7>Y (379''), E12 (384''), M14 (386''), F85.1>A (433''), Y86>V (435'') (369''-473''), CHS (474''-475'')) (244''-475'')]; dimer (234-254'': 237-257'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Immunoglobulin G1, bispecific, anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal KLCB245 single-chain variable region fragment VL-(peptide linker (synthetic 20-amino acid))-VH) fusion protein with immunoglobulin G1 [5-serine,19-alanine,20-alanine,50-serine,81-tyrosine,135-valine,136-tyrosine,190-alanine,192-valine] (human allotype G1m(17) γ1-chain hinge-CH2-CH3 domain fragment), (254→234′),(257→237′)-bis(disulfide) with immunoglobulin G1 [242-alanine,243-alanine,273-serine,358-valine,374-leucine,400-leucine,402-tryptophan] anti-(human kallikrein 2) (human-Mus musculus monoclonal KLCB245 allotype G1m(17) γ1-chain) disulfide with human-Mus musculus monoclonal KLCB245 κ-chain

PASRITAMIG [USAN]

Pasritamig [WHO-DD]

immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens KLK2 (kallikrein-2, kallikrein related peptidase 2, kallikrein 2 prostatic) and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], Homo sapiens and humanized monoclonal antibody, bispecific, bivalent

pasritamig [INN]